ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2018
Applications of Bioengineered 3D Tissue and Tumor Organoids in Drug Development and Precision Medicine: Current and Future.
Review in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 73 citations in OpenAlex.
- Development and Transformation of Veterinary Experimental In Vitro Models: From 2D Culture to 3D Organoids.Animals : an open access journal from MDPI · 2026Review
- Review
- From laboratory to clinic: a precise treatment strategy of mesenchymal stem cells-derived exosomes pretreated by simulating disease microenvironment.Frontiers in immunology · 2025Review
- Tuning a bioengineered hydrogel for studying astrocyte reactivity in glioblastoma.Acta biomaterialia · 2024Article
- Drug-Resistance Biomarkers in Patient-Derived Colorectal Cancer Organoid and Fibroblast Co-Culture System.Current issues in molecular biology · 2024Article
- Bioengineered in vitro three-dimensional tumor models in endocrine cancers.Endocrine-related cancer · 2024Review
- Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development.Theranostics · 2024Review
- Grand challenges in organoid and organ-on-a-chip technologies.Frontiers in bioengineering and biotechnology · 2024Article
- Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.Molecular cancer · 2023Review
- Mammary Glands of Women, Female Dogs and Female Rats: Similarities and Differences to Be Considered in Breast Cancer Research.Veterinary sciences · 2023Review
- Characterization of Biocompatibility of Functional Bioinks for 3D Bioprinting.Bioengineering (Basel, Switzerland) · 2023Review
- Toward better drug development: Three-dimensional bioprinting in toxicological research.International journal of bioprinting · 2023Review
- Scaffold-based three-dimensional cell model of pancreatic cancer is more suitable than scaffold-free three-dimensional cell model of pancreatic cancer for drug discovery.Cytotechnology · 2022Article
- Native human collagen type I provides a viable physiologically relevant alternative to xenogeneic sources for tissue engineering applications: A comparative in vitro and in vivo study.Journal of biomedical materials research. Part B, Applied biomaterials · 2022Article
- Designing Organoid Models to Monitor Cancer Progression, Plasticity and Resistance: The Right Set Up for the Right Question.Cancers · 2022Article
- Exploiting three-dimensional human hepatic constructs to investigate the impact of rs174537 on fatty acid metabolism.PloS one · 2022Article
- 3D Printing: Advancement in Biogenerative Engineering to Combat Shortage of Organs and Bioapplicable Materials.Regenerative engineering and translational medicine · 2022Review
- Strategies for developing complex multi-component in vitro tumor models: Highlights in glioblastoma.Advanced drug delivery reviews · 2022Review
- Intersection of stem cell biology and engineering towards next generationFrontiers in bioengineering and biotechnology · 2022Review
- Reconstructing the tumor architecture into organoids.Advanced drug delivery reviews · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Over the past decade, advances in biomedical and tissue engineering technologies, such as cell culture techniques, biomaterials, and biofabrication, have driven increasingly widespread use of three-dimensional (3D) cell culture platforms and, subsequently, the use of organoids in a variety of research endeavors. Given the 3D nature of these organoid systems, and the frequent inclusion of extracellular matrix components, these constructs typically have more physiologically accurate cell-cell and cell-matrix interactions than traditional 2D cell cultures. As a result, 3D organoids can serve as better model systems than their 2D counterparts. Moreover, as organoids can be biofabricated from highly functional human cells, they have certain advantages over animal models, being human in nature and more easily manipulated in the laboratory. In this review, we describe such organoid technologies and their deployment in drug development and precision medicine efforts. Organoid technologies are rapidly being developed for these applications and now represent a wide variety of tissue types and diseases. Evidence is emerging that organoids are poised for widespread adoption, not only in academia but also in the pharmaceutical industry and in clinical diagnostic applications, positioning them as indispensable tools in medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.